BioSpace News Archive

BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today reported new data from its clinical program for Plinabulin, which demonstrated a superior immune profile compared to Neulasta (pegfilgrastim) based on promyelocytes and immature neutrophil data from clinical study.

Veracyte, Inc. announced today the publication of “real world” data showing that the Afirma® Genomic Sequencing Classifier (GSC) enables even more patients to avoid unnecessary surgery in thyroid cancer diagnosis compared to the company’s flagship, original Afirma Gene Expression Classifier (GEC). The findings are published online in Endocrine Practice, the journal of the American Association of Clinical Endocrinologists.

Recognized at National Philanthropy Day event on November 5, 2018

Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that clinical data on AKCEA-APO(a)-LRx in patients with established cardiovascular disease (CVD) and elevated levels of lipoprotein(a), or Lp(a), will be presented at the American Heart Association Scientific Sessions in Chicago November 10-12, 2018.

CMI Time Management, a leading global provider of innovative workforce and resource management products for companies in a variety of major industries, announced the release of the latest entry in its proprietary TouchTime line of data collection terminals.

Oxford Gene Technology (OGT), The Molecular Genetics Company, has announced that it has expanded its direct sales of Cytocell Fluorescence In Situ Hybridisation (FISH) products to include the Asia-Pacific (APAC) region.

David T. Feinberg, MD, Stepping Down to Pursue New Opportunity

InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company developing first-of-their-kind inhaled therapies for cardiovascular diseases, today provided a corporate update highlighting fundraising and clinical development milestones.

Altasciences is excited to announce the completion of their laboratory expansion.

ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today reported financial results for the quarter ended 30 September 2018 and provided an update on its clinical activities.